SpaceX stock down 32% from peak SpaceX closed at $153.23, down from its all-time high of $225.64. The company's IPO was record-setting at $135. The stock's performance is being closely watched, particularly given its $75 billion valuation. Former Nasdaq CEO
The decision leaves intact a lower-court ruling overturning a $45 million damages award against Natera in a dispute with CareDx. The U.S. Supreme Court declined to review CareDx’s appeal in its false-advertising dispute with Natera Inc. (NASDAQ:NTRA), affirming lower-court
DexCom expands its glucose biosensor use to non-insulin-dependent children aged 2+, aiming to broaden market access starting July. DexCom (NASDAQ:DXCM) received FDA clearance to extend its Stelo Glucose Biosensor to children aged 2 and older who do not use insulin. The mov
Regeneron's FDA priority review for cemdisiran and hedge fund interest highlight its AI-driven healthcare pipeline. Regeneron Pharmaceuticals (NASDAQ:REGN) secured FDA priority review for cemdisiran, targeting generalized myasthenia gravis, with a November 2026 action date
The new orthopaedic device offers faster speeds and improved precision for complex surgical procedures, the company said. Stryker Corporation (SYK) launched TPX HD, a small bone power tool designed for high-demand orthopaedic surgeries, including joint revisions and minima
A Pfizer executive highlights China’s dominance in oncology clinical trials and faster, cheaper drug development compared to Europe. Pfizer’s Chief International Commercial Officer stated China now accounts for 40% of global oncology clinical studies, surpassing Europe in
A Los Angeles jury ruled Johnson & Johnson was not liable for ovarian cancer claims linked to its talc-based baby powder. A Los Angeles jury determined Johnson & Johnson was not negligent in a lawsuit alleging its talc products caused ovarian cancer in three women. The cas
LLY plans to roll out its oral obesity treatment in Europe and Britain by early 2027, targeting direct-to-patient sales via telehealth partnerships. Eli Lilly will launch its oral weight-loss drug in Europe and Britain in the second half of 2026 or early 2027. The company
US equities declined as semiconductor shares dropped, pressuring the Nasdaq amid reports OpenAI may delay its IPO until 2027. US stock indexes closed lower as a sell-off in heavyweight chip producers weighed on the Nasdaq. AI and memory stocks led declines, with semiconduc
General Motors has retired 500 million shares worth $30 billion over five years, fueling investor returns amid strong truck and SUV demand. General Motors (NYSE: GM) stock has climbed 116% over the past three years, outpacing the S&P 500’s 21% gain in the last 12 months. T
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.